Articles tagged with Lymphoma
A recent study by the RAND Corporation has confirmed a link between breast implants and anaplastic large cell lymphoma (ALCL), a rare type of immune system cancer. The disease takes a slow course and can be controlled by surgical removal of the implant and surrounding tissue.
Researchers at North Carolina State University used a genetic model of dogs to identify genes involved in human non-Hodgkin lymphoma. The study found that only a few genes were shared between dogs and humans, suggesting that the genetic changes associated with the cancer are much less complex in canines.
Researchers at Sbarro Health Research Organization have discovered a new mechanism for INK4/ARF protein inactivation in Burkitt's lymphoma. The study suggests that reactivating tumor suppressor genes p16 and p14 could lead to the inhibition of cell proliferation and induction of apoptosis, offering potential new treatment avenues.
Researchers developed computer-assisted diagnosis tools to grade Follicular Lymphoma samples more accurately and efficiently. The tools use high-resolution images and machine learning algorithms to identify malignant regions and classify disease grades, promising faster and more accurate diagnoses.
The PRIMA study found that rituximab-maintenance therapy significantly improved progression-free survival and response rates compared to no treatment in patients with follicular lymphoma. After 2 years, 71.5% of patients in the rituximab group achieved complete or unconfirmed complete response compared to 52.2% in the observation group.
The personalized vaccine is effective in preventing recurrence among certain follicular lymphoma patients with a specific protein on their tumor cells. The vaccine improves disease-free survival by nearly two years compared to placebo treatments.
Researchers present promising new treatment options for advanced asymptomatic follicular lymphoma, mantle cell lymphoma, and early Hodgkin disease. The study shows that upfront rituximab therapy can significantly prolong the time until a patient may require chemotherapy.
A new mutation in the B cell activating factor receptor (BAFF-R) has been identified as a potential contributor to non-Hodgkin's lymphoma. The mutation amplifies BAFF signaling, leading to increased B cell function and cancer progression.
A randomized study found that standard chemotherapy and radiation therapy remain the most effective treatment for early, intermediate-stage Hodgkin's lymphoma patients. The study also showed that a more intensive chemotherapy regimen is not more effective than standard ABVD chemotherapy in treating this group of patients.
Researchers at the University of Illinois have identified a new target for cancer therapy in dogs and tested a compound that arrested tumor growth and induced partial remission. The study suggests that the treatment could be effective and safe, potentially adding to existing lymphoma treatments.
The American Society of Hematology will honor six scientists with significant contributions to the understanding and treatment of hematologic diseases. Volker Diehl, Sanford Shattil, David T. Scadden, Leonard I. Zon, Barry S. Coller, and Joel S. Bennett will receive awards for their pioneering research in Hodgkin lymphoma, platelet cel...
Researchers developed multicolor quantum dot staining to identify Reed-Sternberg cells, characteristic of Hodgkin's lymphoma. This method allows for rapid detection and identification of rare malignant cells from heterogeneous tissue specimens.
A study published in the American Society of Clinical Oncology annual meeting showed that lenalidomide significantly improved response rates and complete remission in patients with transformed lymphoma. Patients treated with lenalidomide had a remarkable response rate, with some experiencing complete remission for over a year.
Researchers found that H. pylori eradication therapy may be an initial treatment option for localized, H. pylori-negative gastric MALT lymphoma. The study adds information to establish strategies for patients with localized H. pylori-negative gastric MALT lymphoma.
Researchers at University of Leeds and Charité University Medical School have discovered that 'junk' DNA promotes cancer cell growth in patients with Hodgkin's lymphoma. Long terminal repeats (LTRs) are a form of genetic material that can activate cancer genes, leading to the growth of cancer cells.
Researchers at the Mayo Clinic found that people with higher vitamin K intakes from their diet had a lower risk of developing Non-Hodgkin lymphoma. Vitamin K intake was estimated from a food questionnaire and was associated with a significant protective effect against the disease.
The Lymphoma Research Foundation has published a report on Mantle Cell Lymphoma, highlighting the disease's rarity and the need for further research. The report, based on the 2009 MCL Scientific Workshop, aims to accelerate advances in MCL treatment and improve patient outcomes.
A new study demonstrates advances in optimizing treatments and quality of life for patients with multiple myeloma. The research explores optimal induction therapies, advance care planning, and a potential new first-line therapy for non-Hodgkin lymphoma.
A new study demonstrates the effectiveness of immunotherapy using specialized white blood cells to prevent or treat EBV-lymphoma in patients who have received a hematopoietic stem cell transplant. The therapy achieved sustained complete remission in 85% of treated patients and long-term protection for up to nine years.
The Lymphoma Research Foundation has awarded grants of $300,000 and $200,000 to Drs. David Frank and Thomas Kipps for their research on Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). The grants aim to develop new treatments for patients with refractory disease.
A three-year study by University of Alberta researchers found that aerobic exercise training significantly improved physical functioning and overall quality of life in patients with lymphoma. The study showed a 46.4% complete response rate in the exercise group, compared to 30.8% in the usual care group.
Cold Spring Harbor Laboratory scientists uncover a large cache of genes that act as built-in barriers against cancer, including over 10 new tumor suppressor genes. The study reveals that even partial loss of function in these genes can accelerate tumor growth.
Researchers have discovered an experimental compound that selectively kills cancerous B lymphocytes while allowing normal B cells to survive. The study found that K252a disrupts a key signaling pathway involved in the growth of lymphoma cells, offering new hope for treating non-Hodgkin lymphoma.
Researchers found that adding high-dose cytarabine to methotrexate therapy improved complete remission rates (46%) and overall response rates (69%) in patients with primary central nervous system lymphoma. The combination also resulted in a lower risk of relapse and improved progression-free survival.
A new analysis reveals that adolescents and young adults with blood-related cancers have better long-term survival rates than those diagnosed in the 1980s. However, survival rates in this age group are still lower than those seen in younger children and some older adults.
Dr. Kai Fu receives $300K Clinical Investigator Career Development Award for mantle cell lymphoma research, focusing on miR-17~92 expression and its correlation with patient survival. The funding aims to support a pre-clinical study to determine the effectiveness of suppressing miR-17~92 in improving chemotherapy outcomes.
Researchers at UC Berkeley and TGen found a gene variant, rs6457327, associated with nearly twice the risk of developing follicular lymphoma, a cancer of the body's disease-fighting network. The presence of the G allele was protective against the disease, while the A allele increased risk.
Patients treated for Hodgkin lymphoma with radiation therapy have a substantially higher risk of stroke. After a median follow-up of almost 18 years, 96 patients developed cerebrovascular disease, with the incidence rate for stroke being 2.2 times that in the general population. Risk factors include radiation to the neck and mediastinum.
Researchers at Stanford University School of Medicine developed a machine that can analyze tiny blood samples for cancer-associated proteins, detecting subtle changes in protein modifications. The technique may provide a faster and less invasive way to track solid tumors and monitor treatment response.
A new study has found that maintenance rituximab therapy improves progression-free survival in patients with stage III-IV indolent lymphoma. The treatment showed significant benefits, including a 22% improvement in disease response and a 68% three-year progression-free survival rate.
Patients with relapsed follicular lymphoma who continue on maintenance rituximab therapy after chemotherapy have better overall survival than those without treatment. Rituximab maintenance therapy was associated with a 40% improvement in overall survival relative to observation or retreatment.
Researchers find AID causes genetic malfunctions leading to Burkitt's lymphoma and potentially other cancers. The enzyme, responsible for immune system adaptation, also targets a cancer-promoting gene.
Researchers at USC have identified a key mechanism that occurs in the inception point of many human lymphomas, a process previously unknown. The study found that chromosomal translocations occur at CpG sites in early B-cells, driven by enzymes AID and RAG complex.
A study published by researchers at M.D. Anderson Cancer Center revealed that intense chemotherapy significantly reduces the risk of recurrence in young mantle cell lymphoma patients. In a median follow-up of seven years, 52% of patients aged 65 or younger achieved disease-free survival.
Mantle cell lymphoma cells rely on heat shock protein 90 to maintain their rapid growth. Researchers are using inhibitors to block this process, causing stress in the cells' machinery. The goal is to trigger apoptosis in cancer cells.
A new study reveals that poorer socioeconomic status increases mortality risk in non-Hodgkin lymphoma patients, while chemotherapy reduces the risk. Ethnic disparities are also observed, with African-Americans less likely to receive chemotherapy and living in poorer communities.
A research article compares CT findings in mesenteric tuberculosis and non-Hodgkin's lymphoma (NHL), revealing specific enhancement patterns and anatomic lymph node distribution. The 'sandwich sign' is more often found in NHL, aiding in differential diagnosis between tuberculosis and untreated NHL involving the small bowel mesentery.
Researchers found Rheb overexpression is sufficient to induce low-grade prostate neoplasias and contributes to lymphoma formation. Targeted inhibition of Rheb shows promise in counteracting tumor progression in both cancers.
A new study reveals that mantle cell lymphoma incidence is increasing, especially among men and Caucasians, with advanced stages detected in nearly 75% of patients. The research also highlights the need for better understanding of the disease's epidemiology and development of novel treatment agents.
Researchers at ESMO Conference Lugano report improved treatment outcomes for aggressive non-Hodgkin's lymphoma patients when chemotherapy is administered every 2 weeks, rather than every 3 weeks.
Researchers used PET scans to analyze 38 patients with non-Hodgkin's lymphoma treated with 90 ibritumomab tiuxetan. The study found that 89% of patients were in complete or partial remission after treatment, with a higher response rate for patients with limited cancer progression.
In a phase II clinical trial, 70% of patients with follicular lymphoma responded to treatment with galiximab and rituximab. The combination regimen achieved complete responses in 44% and partial responses in 26%. Further study is warranted to assess the efficacy and time-to-progression endpoint.
Researchers found that treatments for childhood Hodgkin's lymphoma increase the risk of dying from a second cancer or cardiovascular disease in adulthood. Women are especially vulnerable to breast cancer, while men are at risk of cardiovascular events.
A phase 1 clinical trial showed AME-133v had a potent tumor-halting response in patients with follicular lymphoma. The drug triggered signaling pathways within cells to slow or stop cancer growth, while causing minimal side effects.
A long-term study of twins has led USC researchers to find potential links between Hodgkin lymphoma and levels of an immune response protein, interleukin-12. Lower levels of this protein may increase susceptibility to the disease.
Researchers at the University of Southern California found that combined positron emission tomography (PET) and computed tomography (CT) imaging yields greater accuracy when evaluating response to radiation therapy. This method helps identify complete responders and reduces the need for unnecessary chemotherapy treatments.
The study analyzed data from the Surveillance, Epidemiology and End Results (SEER) Program and found that non-Hodgkin lymphoma patients showed significant improvements in five- and 10-year survival rates, with increases ranging from 26.8 to 27.1 percentage points across all age groups and tumor subtypes.
Researchers found that the antimalarial drug chloroquine effectively prevents cancer in mouse models of two human cancer syndromes, Burkitt lymphoma and ataxia telangiectasia. Chloroquine inhibited the development of Myc-induced lymphomas and ATM-deficient mice, but not p53-deficient mice.
Researchers have found that the Myc protein can stop the production of at least 13 microRNAs, which help control gene expression. Re-introducing repressed miRNAs into cancer cells suppressed tumor growth in mice, raising hopes for a novel therapy approach.
Researchers at the University of Texas M. D. Anderson Cancer Center report that a milder chemotherapy regimen before stem cell transplant resulted in complete remission for 45 of 47 patients with relapsed follicular lymphoma. Long-term follow-up showed improved overall survival and progression-free survival rates.
A new study has identified a direct link between Plasmodium falciparum antigens and Epstein-Barr virus (EBV) reactivation, increasing the risk of Burkitt lymphoma in children living in malaria-endemic areas. The researchers found that certain proteins from P. falciparum can spur latent EBV-infected cells into active production.
A University of Michigan study found that 86% of patients with follicular lymphoma survived after 8 years of treatment with Bexxar, a radioimmunotherapy drug. This success rate compares favorably to state-of-the-art chemotherapy regimens, making Bexxar an attractive option for patients.
Adding radioimmunotherapy to chemotherapy increased complete response rates for patients with follicular lymphoma, a slow-growing type of non-Hodgkin's lymphoma. Over 90% of study patients responded completely to the treatment, with limited side effects.
Alcohol drinking has been associated with a reduced risk of renal cell cancer. Childhood leukemia and lymphoma survivors face an elevated risk of secondary cancers, while treatment with clodronate did not improve survival for men with localized prostate cancer.
A study found that hepatitis C virus (HCV) infection increases the risk of non-Hodgkin lymphoma by 20-30% and Waldenström macroglobulinemia by nearly three-fold. HCV is also linked to an increased risk of nonmalignant plasma cell disorders.
People infected with hepatitis C virus (HCV) are at an increased risk of developing certain lymphomas, including non-Hodgkin's lymphoma and Waldenström's macroglobulinemia. The risk was found to be 20-30% higher for HCV-infected patients compared to uninfected patients.
A study by radiologists at the University of Minnesota found that PET-CT detects muscular lymphoma more effectively than CT alone, revealing muscle involvement that may be overlooked. This breakthrough suggests that incorporating PET-CT into imaging protocols can lead to more accurate diagnoses and treatment plans.
Researchers at the University of Helsinki have discovered a new effective treatment modality for KSHV-infected lymphomas by reactivating the p53 pathway. The study shows that Nutlin-3a, a small-molecule inhibitor, selectively induces massive apoptosis in PEL cells.
Researchers discovered Nutlin-3a induces apoptosis in human PEL cell lines by disrupting LANA-p53 interaction, causing substantial tumor regression in mice with established PEL. This reactivation of the p53 pathway may provide a viable therapeutic option for individuals with KSHV-induced lymphomas.
International team develops standardized guidelines for assessing lymphoma treatment response, incorporating new imaging technologies. The revised guidelines aim to improve therapies and facilitate the development of new treatments.